Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100656 | 0.93 | MTNR1A (0.49) | MTNR1AMTNR1BTAAR1CYP1A2HDAC1 | |
| SCHEMBL10596068 | 0.91 | AKR1C3 (0.49) | AKR1C3AKR1C2MTNR1AMTNR1BTAAR1 | |
| SCHEMBL6050076 | 0.90 | MTNR1A (0.49) | AKR1C3AKR1C2AKR1C1PTGS1MTNR1A | |
| SCHEMBL9145931 | 0.89 | ALDH1A1 (0.56) | AKR1C3AKR1C2AKR1C1TAAR1CNR2 | |
| SCHEMBL5077290 | 0.85 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC6 | |
| SCHEMBL11815553 | 0.85 | MITF (0.54) | AKR1C3MTNR1AMTNR1B | |
| SCHEMBL30811394 | 0.83 | ALDH1A1 (0.56) | HDAC1 | |
| SCHEMBL11820853 | 0.82 | ABCB1 (0.51) | AKR1C3MTNR1AMTNR1B | |
| SCHEMBL24440174 | 0.80 | TAAR1 (0.53) | MTNR1AMTNR1BTAAR1CYP1A2HDAC1 | |
| SCHEMBL16147991 | 0.79 | SLC1A5 (0.58) | MTNR1AMTNR1BTAAR1CYP1A2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0838459-B1 | Naphthyl compounds, compositions, and methods | LILLY CO ELI (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-0835867-B1 | 1-Aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods | LILLY CO ELI (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-0835868-B1 | 2-Aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods | LILLY CO ELI (US) | 2001-08-29 | — | — | EP | disclosed |
| US-5952350-A | INHIBITING BONE LOSS OR BONE RESORPTION, PARTICULARLY OSTEOPOROSIS, AND CARDIOVASCULAR DISORDERS INCLUDING HYPERLIPIDEMIA, AND ESTROGEN DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1999-09-14 | — | — | US | disclosed |
| US-5929090-A | NOVEL COMPOUNDS FOR TREATING ESTROGEN DEPRIVATION CAUSED BY MENOPAUSE OR OVARIECTOMY; TREATING OSTEOPOROSIS, CARDIOVASCULAR DISEASES, AND ENDOMETRIOSIS | ELI LILLY AND COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5916916-A | USEFUL AS SELECTIVE ESTROGEN RECEPTOR MODULATORS. | ELI LILLY AND COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0838459-A1 | Naphthyl compounds, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0835867-A1 | 1-Aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0835868-A1 | 2-Aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |